Myriad Defends Cancer Gene Patents To Supreme Court
Myriad Genetics Inc. urged the U.S. Supreme Court on Thursday to reject a challenge to the validity of its patents on breast cancer genes, saying that isolated genes are clearly patent-eligible...To view the full article, register now.
Already a subscriber? Click here to view full article